𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Polyclonal hypergammaglobulinemia at the onset of acute myeloid leukemia in children

✍ Scribed by G. Surico; P. Muggeo; V. Muggeo; A. Lucarelli; C. Novielli; V. Conti; N. Rigillo


Publisher
Springer
Year
1999
Tongue
English
Weight
55 KB
Volume
78
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Skeletal scintigraphy and radiography at
✍ Clausen, Niels ;GΓΈtze, Hans ;Pedersen, Aase ;Riis-Petersen, JΓΈRn ;Tjalve, Elsebe πŸ“‚ Article πŸ“… 1983 πŸ› John Wiley and Sons 🌐 English βš– 474 KB

Technetium skeletal scintigraphy performed at the time of diagnosis was compared with pain and radiographs in 24 children with acute lymphocytic leukemia. Localized intense uptake of the labeled compound in one or several metaphyses and increased uptake in diaphyses were typical findings by scintigr

HLA system affects the age-at-onset in c
✍ Fatma Savran Oguz; Sevgi Kalayoglu; A. Sarper Diler; Hilmi Tozkir; Deniz Sargin; πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 106 KB πŸ‘ 1 views

## Abstract Chronic myeloid leukemia (CML) occurs from childhood to old age. The adult form is characterized by the presence of Philadelphia chromosome resulting from bcr/abl translocation. The BCR–ABL fusion proteins are immunogenic, and the junctional sequences show unique HLA class I and class I

Progress in the treatment of acute myelo
✍ Farhad Ravandi; Alan K. Burnett; Edward D. Agura; Hagop M. Kantarjian πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 131 KB πŸ‘ 2 views

## Abstract Significant progress in understanding the mechanisms leading to the development of acute myeloid leukemia (AML) has led to the identification of numerous molecular abnormalities that may be responsible for leukemogenesis. Over the same period, large trials have established standard regi

Gemtuzumab ozogamicin in the treatment o
✍ Francis Giles; Elihu Estey; Susan O'Brien πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 484 KB πŸ‘ 2 views

## Abstract Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized anti‐CD33 antibody (hP67.6) linked to N‐acetyl‐γ calicheamicin 1,2‐dimethyl hydrazine dichloride, a potent enediyne antitumor antibiotic. GO was approved conditionally by the Federal Drug Administration